May 15, 2024 4:34pm

After soft reading on consumer prices, a deceleration from March. "Core" inflation striped out the cost of food and gas also cooled as retail sales fell flat

Financing: Solid Biosciences files shelf/prospectus for $300 M Debt Securities, Common Stock, Preferred Stock, Depositary Shares, Warrants and Units … https://investors.solidbio.com/node/10616/html

As I had stated, “let’s not forget about volatility”

A 360-degree review of the who, why, when and what happened in the sector as the market and economics surround your portfolio’s defense or offence.

Never leave an investor uninformed! A trusted source of factual reporting!

The present and future value of RegMed Investors (RMi) NEWS sheds light on the stem, cell and gene therapy sector’s risks to share pricing and the sector’s upside acrobatics and potential downslides.

I write this blog/newsletter about – facts in evidence! 

 

Wednesday: The Dow closed UP +349.89 points or +0.88%, the S&P closed UP +61.47 points or +1.17% while the Nasdaq closed UP +231.21 points or +1.40%

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

The S&P 500 and Nasdaq popped to record highs Wednesday, adding to their strong 2024 performances, boosted by a lighter-than-expected U.S. consumer inflation report.

Economic Data Docket: The consumer price index rose 0.3% for the month of April, less than the Dow Jones estimate for a 0.4% monthly increase. The gauge increased 3.4% year over year, in line with expectations. Monthly and yearly numbers for core CPI, which excludes volatile food and energy prices, were both in line as well.

  • Retail sales remained flat in April. Economists anticipated a 0.4% jump.

 

RegMed Investors (RMi) - Q1/24 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628

 

Advance/Decline (A/D) Line:

  • Wednesday’s advance/decline line at the open was positive with 22 incliner, 11 decliners and 2 flats; ending with a positive close of 24 incliners, 6 decliners and 5 flats

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”:

Q2/24: 8 positive and 3 negative closes

  • April; 16 negative and 6 positive closes

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB was up +1.38% and the XBI was up +2.02%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was down -0.97 point or -7.30 % at 12.44

 

Wednesday’s Closing Down (6 of 6):

  • Alnylam Pharmaceuticals (ALNY -$0.49 after Tuesday’s -$2.00 after Monday’s -$0.58),
  • Sage Therapeutics (SAGE -$0.28 after Tuesday’s -$0.18),
  • Solid Biosciences (SLDB -$0.27 after Tuesday’s +$0.21 after Monday’s -$0.64),
  • Adverum Biotechnologies (ADVM -$0.18 after Tuesday’s -$0.24 after Monday’s -$0.13),
  • Compass Therapeutics (CMPX -$0.075),
  • Brainstorm Cell Therapeutics (BCLI -$0.016 after Tuesday’s -$0.0479),

Flat (5):

  • Verve Therapeutics (VERV)
  • Caribou Biosciences (CRBU)
  • bluebird bio (BLUE)
  • Mesoblast (MESO $0.00 after Tuesday’s +$0.22 after Monday’s -$0.38),)
  • Bellicum Pharmaceuticals (BLCM) – dropped)

Wednesday’s Closing Up (10 of 24):

  • Blueprint Medicine (BPMC +$1.33 after Tuesday’s -$2.59 after Monday’s +$1.35),
  • CRISPR Therapeutics (CRSP +$1.25 after Tuesday’s +$0.06),
  • Ionis Pharmaceuticals (IONS +$0.94 after Tuesday’s -$0.53 after Monday’s -$0.28,
  • Vericel (VCEL +$0.88),
  • BioLife Solutions (BLFS +$0.56 after Tuesday’s +$1.77 after Monday’s +$1.12),
  • Intellia Therapeutics (NTLA +$0.49 after Tuesday’s +$0.31 after Monday’s +$0.96),
  • Regenxbio (RGNX +$0.43 after Tuesday’s +$0.06),
  • Harvard Apparatus RT (OTCQB: HRGN +$0.36 with 200 shares traded after Tuesday’s and Monday’s flats),
  • Editas Medicine (EDIT +$0.32),
  • Beam Therapeutics (BEAM +$0.30 after Tuesday’s -$0.21 after Monday’s +$2.76),

 

Q2/24 – May

  • Wednesday closed positive with 24 incliners, 6 decliners and 5 flats

 

The BOTTOM LINE:  The cell and gene therapy stocks stayed positive – 3 sessions in a row and 8 of 11 so far this May.

Today:

  • Solid Biosciences (SLDB) reported a Q1/24 net loss of -$24.3 M or -$0.64 per share with a cash position of S206.1 M, with a runway until 2026

Reporting: https://www.regmedinvestors.com/articles/11628   

All three major averages closed near or at all-time highs.

  • The relatively cool inflation reading led the 10-year Treasury yield to fall 4.35%, its lowest level in a month, and sparked new bets on Fed rate cuts as soon as September.

 

The top three (3) performing in the session:  

  • Wednesday: Blueprint Medicine (BLMC), CRISPR Therapeutics (CRSP) and Ionis Pharmaceuticals (IONS) 
  • Tuesday: BioLife Solutions (BLFS), Generation Bio (GBIO (GBIO) and Intellia Therapeutics (NTLA)
  • Monday: CRISPR Therapeutics (CRSP), Beam Therapeutics (BEAM) and Blueprint Medicine (BLMC)

The worst three (3) in the session:

  • Wednesday: Alnylam Pharmaceuticals (ALNY), Sage Therapeutics (SAGE) and Solid Biosciences (SLDB)
  • Tuesday: Blueprint Medicine (BLMC), Alnylam Pharmaceuticals (ALNY) and Ionis Pharmaceuticals (IONS) 
  • Monday: Solid Biosciences (SLDB), Alnylam Pharmaceuticals (ALNY) and Mesoblast (MESO)

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.